| DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer E Galle, B Thienpont, S Cappuyns, T Venken, P Busschaert, M Van Haele, ... Clinical epigenetics 12, 1-19, 2020 | 70 | 2020 |
| Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review S Cappuyns, V Corbett, M Yarchoan, RS Finn, JM Llovet JAMA oncology, 2023 | 14 | 2023 |
| Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma C Brackenier, L Kinget, S Cappuyns, C Verslype, B Beuselinck, ... Cancers 15 (2), 348, 2023 | 8 | 2023 |
| DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clin Epigenetics 12: 27 E Galle, B Thienpont, S Cappuyns, T Venken, P Busschaert, M Van Haele, ... | 5 | 2020 |
| PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced … S Cappuyns, G Philips, V Vandecaveye, B Boeckx, R Schepers, ... Nature Communications 14 (1), 7825, 2023 | 3 | 2023 |
| Combination therapies for advanced hepatocellular carcinoma: biomarkers and unmet needs S Cappuyns, JM Llovet Clinical Cancer Research 28 (16), 3405-3407, 2022 | 3 | 2022 |
| Abstract PR03: Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing S Cappuyns, G Philips, V Vandecaveye, C Verslype, E Van Cutsem, ... Clinical Cancer Research 28 (17_Supplement), PR03-PR03, 2022 | 1 | 2022 |
| Pre-treatment cross-talk between the tumoural and peripheral immune system predicts response to checkpoint inhibition in advanced HCC: A single-cell study S Cappuyns, G Philips, V Vandecaveye, C Verslype, E Van Cutsem, ... Journal of Hepatology 77, S385-S385, 2022 | 1 | 2022 |
| Applications of single-cell multi-omics in liver cancer F Peeters, S Cappuyns, M Piqué-Gili, G Phillips, C Verslype, ... JHEP Reports, 101094, 2024 | | 2024 |
| Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors YL Wu, S Cappuyns, A Loh, S Sun, S Lewis, MW Sung, M Schwartz, ... BJC Reports 2 (1), 8, 2024 | | 2024 |
| HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply JM Llovet, S Cappuyns, RS Finn JAMA oncology, 2024 | | 2024 |
| PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA S Cappuyns, M Pique-Gili, R Esteban-Fabro, G Philips, R Pinyol, ... HEPATOLOGY 78, S1871-S1872, 2023 | | 2023 |
| The ongoing search for biomarkers of response to systemic therapy in advanced hepatocellular carcinoma. S Cappuyns | | 2023 |
| Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures S Cappuyns, M Piqué-Gili, R Esteban-Fabró, G Philips, R Pinyol, ... Journal of Hepatology 78, S52-S53, 2023 | | 2023 |
| PD1-negative CD45RA effector-memory CD8 T-cells are essential for response to checkpoint inhibition in advanced hepatocellular carcinoma S Cappuyns, G Philips, V Vandecaveye, B Boeckx, R Schepers, ... Journal of Hepatology 78, S524-S525, 2023 | | 2023 |
| A pan-cancer single-cell tumor micro-environment atlas predictive of immunotherapy response F Lodi, S Vanmassenhove, E Donders, P Van Mol, A Franken, ... Cancer Research 83 (7_Supplement), 5785-5785, 2023 | | 2023 |
| TRANSLATING SINGLE-CELL TO BULK RNA SEQUENCING DATA TO IDENTIFY RESPONDERS TO CHECKPOINT INHIBITION IN ADVANCED HEPATOCELLULAR CARCINOMA S Cappuyns, R Esteban-Fabro, G Philips, V Vandecaveye, M Pique-Gili, ... Hepatology 76, S1275-S1276, 2022 | | 2022 |
| Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post‐progression systemic therapy C Van Laeken, T Taelman, S Cappuyns, G Maleux, V Vandecaveye, ... Liver Cancer International 3 (3), 128-136, 2022 | | 2022 |
| PD-6 DNA methylome as a potential biomarker in biliary brushes and bile fluid samples to differentiate between benign and malignant biliary stenosis S Cappuyns, T Venken, S Stoffels, G Philips, W Laleman, ... Annals of Oncology 33, S241, 2022 | | 2022 |
| Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence? S Cappuyns, M Verbesselt, A Van De Bruaene, J Bogaert, L Michaux, ... European Heart Journal-Case Reports 6 (2), ytac084, 2022 | | 2022 |
